{"transactions":[{"id":2325545,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":128977,"kind":"person","name":"Ullerich Melissa Vera","position":1,"cik":"0001889813","reported_name":"Ullerich Melissa Vera","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Communications Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-03-19T01:15:35.000Z","date":"2022-03-16","kind":"grant","acquired":true,"shares":16405,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors."}],"balance_after":16405,"derivative":{"exercise_price":1.78,"expiration_date":"2032-03-16","underlying":"Common Stock","underlying_shares":16405},"source":{"system":"sec-edgar","filing":"0000899243-22-011662","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000089924322011662/doc4.xml","form_type":"4"}},{"id":2535062,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":128977,"kind":"person","name":"Ullerich Melissa Vera","position":1,"cik":"0001889813","reported_name":"Ullerich Melissa Vera","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Communications Officer"}}],"security":"Earnout Rights (Restricted Stock Units)","published_at":"2021-10-27T01:48:29.000Z","date":"2021-10-22","kind":"grant","acquired":true,"shares":50988,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the \"Earnout Shares\"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"25% of the Earnout Shares will be released if within the five-year period after the closing (the \"Earnout Period\"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the \"Earnout Shares\"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"25% of the Earnout Shares will be released if within the five-year period after the closing (the \"Earnout Period\"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the \"Earnout Shares\"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the Earnout Shares will be released if within the five-year period after the closing (the \"Earnout Period\"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the \"Earnout Shares\"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]"}],"balance_after":50988,"derivative":{"underlying":"Common Stock","underlying_shares":50988},"source":{"system":"sec-edgar","filing":"0001493152-21-026383","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026383/ownership.xml","form_type":"4"}},{"id":2535061,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":128977,"kind":"person","name":"Ullerich Melissa Vera","position":1,"cik":"0001889813","reported_name":"Ullerich Melissa Vera","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Communications Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-10-27T01:48:29.000Z","date":"2021-10-22","kind":"grant","acquired":true,"shares":104689,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, March 29, 2020, with 1/3 vesting on the first anniversary of the Vesting Start Date and the remaining balance to vest on a monthy basis for a period of 24 months thereafter, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, March 29, 2020, with 1/3 vesting on the first anniversary of the Vesting Start Date and the remaining balance to vest on a monthy basis for a period of 24 months thereafter, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date."}],"balance_after":104689,"derivative":{"exercise_price":1.88,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":104689},"source":{"system":"sec-edgar","filing":"0001493152-21-026383","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026383/ownership.xml","form_type":"4"}},{"id":2535060,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":128977,"kind":"person","name":"Ullerich Melissa Vera","position":1,"cik":"0001889813","reported_name":"Ullerich Melissa Vera","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Communications Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-10-27T01:48:29.000Z","date":"2021-10-22","kind":"grant","acquired":true,"shares":58161,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, November 1, 2018, with 1/3 vesting on the first anniversary of the Vesting Start Date and the remaining balance to vest on a monthy basis for a period of 24 months thereafter, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, November 1, 2018, with 1/3 vesting on the first anniversary of the Vesting Start Date and the remaining balance to vest on a monthy basis for a period of 24 months thereafter, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date."}],"balance_after":58161,"derivative":{"exercise_price":1,"expiration_date":"2028-11-01","underlying":"Common Stock","underlying_shares":58161},"source":{"system":"sec-edgar","filing":"0001493152-21-026383","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026383/ownership.xml","form_type":"4"}},{"id":2535059,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":128977,"kind":"person","name":"Ullerich Melissa Vera","position":1,"cik":"0001889813","reported_name":"Ullerich Melissa Vera","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Communications Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-10-27T01:48:29.000Z","date":"2021-10-22","kind":"grant","acquired":true,"shares":6979,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option is fully vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":6979,"derivative":{"exercise_price":1.25,"expiration_date":"2030-04-27","underlying":"Common Stock","underlying_shares":6979},"source":{"system":"sec-edgar","filing":"0001493152-21-026383","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026383/ownership.xml","form_type":"4"}}]}